Management of Osteoporosis in Elderly Females with Prior Bisphosphonate Use

Initial Risk Reassessment and Treatment Decision

The American College of Physicians recommends reassessing the current fracture risk and bone mineral density in elderly females with moderate fracture risk who previously took bisphosphonates, and restarting oral bisphosphonate therapy if they remain at moderate-to-high risk 1, 6
The American College of Physicians provides a strong recommendation for bisphosphonates in postmenopausal women with osteoporosis, based on high-certainty evidence for fracture reduction 1, 6
Bisphosphonates reduce vertebral fractures by approximately 50% and hip fractures by 40-50% over 3 years in high-risk patients, according to the American College of Physicians 1, 6
Prior bisphosphonate use does not diminish efficacy upon restarting—the drugs retain their antifracture benefits, as stated by the American College of Physicians 1, 6

Ensure adequate calcium (1,200 mg/day) and vitamin D (800-1,000 IU/day) intake, regardless of whether pharmacologic therapy is restarted, as recommended by the American College of Physicians 1, 2
Target serum 25(OH)D levels above 32 ng/mL, as vitamin D deficiency attenuates bisphosphonate efficacy and increases hypocalcemia risk, according to the American College of Physicians 2

If oral bisphosphonates are contraindicated or not tolerated, use intravenous zoledronic acid (5mg annually) for adherence concerns or gastrointestinal intolerance, as recommended by the American College of Physicians 1, 2
Denosumab (60mg subcutaneously every 6 months) can be used as second-line if bisphosphonates are contraindicated, according to the American College of Physicians 1, 6
Anabolic agents (romosozumab or teriparatide) can be used only if the patient is at very high risk (multiple prior fractures or T-score < -3.0), as stated by the American College of Physicians 1, 6

Never restart bisphosphonates without correcting vitamin D deficiency first, as this increases hypocalcemia risk, particularly with intravenous formulations, according to the American College of Physicians 2
Complete any necessary dental work before restarting therapy to minimize osteonecrosis of the jaw risk, though this remains rare (< 1 per 10,000 patient-years), as recommended by the American College of Physicians 7
Ensure proper oral bisphosphonate administration: take with full glass of water on empty stomach, remain upright for 30 minutes to prevent esophageal complications, according to the American College of Physicians 2